{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:48:23Z","timestamp":1790938103866,"version":"4.1.0"},"reference-count":31,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Polatuzumab vedotin (pola) is a CD79B-targeting antibody-drug conjugate with significant clinical activity in systemic diffuse large B-cell lymphoma. However, the ability of pola to penetrate the blood-brain barrier (BBB) and induce responses in central nervous system (CNS) lymphoma (CNSL) is unknown. Since other antibody-based therapies can partially penetrate the BBB to induce clinical responses in CNSL and other CNS malignancies, we hypothesized that pola would also partially penetrate the BBB, which could support its evaluation in future CNSL clinical trials. To test this hypothesis, we first evaluated the preclinical efficacy of pola in primary and secondary CNSL xenografts, where we observed that pola significantly decreased CNS tumor burden and prolonged survival in mice. To extend these findings, we compiled a clinical case series of 3 patients with CNSL treated with pola-based treatment. Here, on-treatment cerebrospinal fluid (CSF) samples revealed pola CSF drug concentrations exceeding its established 50% inhibitory concentration, with CSF drug levels being 0.56% to 1.31% of those in plasma. Interestingly, 2 of the 3 patients with CNSL achieved a complete response to pola-based treatment. In summary, these data indicate pola is effective against preclinical CNSL models and can partially penetrate the BBB in patients with CNSL, which together provide support for the evaluation of pola-based treatment in future clinical trials of primary and secondary CNSL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017181","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:19:41Z","timestamp":1759951181000},"page":"6425-6431","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetration"],"prefix":"10.1182","volume":"9","author":[{"given":"Lei","family":"Gao","sequence":"first","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"},{"name":"2Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avyakta","family":"Kallam","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"},{"name":"2Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7917-5713","authenticated-orcid":false,"given":"Geoffrey","family":"Shouse","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"},{"name":"2Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8291-6546","authenticated-orcid":false,"given":"John H.","family":"Baird","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"},{"name":"2Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Pak","sequence":"additional","affiliation":[{"name":"3Department of Pharmacy, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4277-3602","authenticated-orcid":false,"given":"Yue","family":"Qin","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"},{"name":"2Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Y.","family":"Song","sequence":"additional","affiliation":[{"name":"4Department of Pathology, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Marcucci","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"},{"name":"5Department of Hematological Malignancies and Translational Science, Beckman Research Institute, City of Hope, Duarte, CA"},{"name":"6Hematopoietic Tissue Biorepository, Shared Resource Core Facility, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy Y.","family":"Ghoda","sequence":"additional","affiliation":[{"name":"5Department of Hematological Malignancies and Translational Science, Beckman Research Institute, City of Hope, Duarte, CA"},{"name":"6Hematopoietic Tissue Biorepository, Shared Resource Core Facility, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Guillen","sequence":"additional","affiliation":[{"name":"6Hematopoietic Tissue Biorepository, Shared Resource Core Facility, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6759-4219","authenticated-orcid":false,"given":"Suk-Joon","family":"Hyung","sequence":"additional","affiliation":[{"name":"7Genentech Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2607-8901","authenticated-orcid":false,"given":"Ola M.","family":"Saad","sequence":"additional","affiliation":[{"name":"7Genentech Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Davis","sequence":"additional","affiliation":[{"name":"7Genentech Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4120-7828","authenticated-orcid":false,"given":"Randall","family":"Dere","sequence":"additional","affiliation":[{"name":"7Genentech Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie L.","family":"Batlevi","sequence":"additional","affiliation":[{"name":"7Genentech Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Meinert","sequence":"additional","affiliation":[{"name":"7Genentech Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1464-5494","authenticated-orcid":false,"given":"Lihua E.","family":"Budde","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"},{"name":"2Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey V.","family":"Danilov","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"},{"name":"2Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9665-7415","authenticated-orcid":false,"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"},{"name":"2Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry W.","family":"Kwak","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"},{"name":"2Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"},{"name":"2Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4103-4288","authenticated-orcid":false,"given":"James K.","family":"Godfrey","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"},{"name":"2Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"6","key":"2025122310012400900_bib1","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"2025122310012400900_bib2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"2025122310012400900_bib3","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/s41375-022-01582-5","article-title":"Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial","volume":"36","author":"Ferreri","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"2025122310012400900_bib4","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/bloodadvances.2023011657","article-title":"Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101","volume":"8","author":"Batchelor","year":"2024","journal-title":"Blood Adv"},{"issue":"33","key":"2025122310012400900_bib5","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1200\/JCO.2015.61.1236","article-title":"High doses of antimetabolites followed by high-dose sequential chemoimmunotherapy and autologous stem-cell transplantation in patients with systemic B-cell lymphoma and secondary CNS involvement: final results of a multicenter phase II trial","volume":"33","author":"Ferreri","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025122310012400900_bib6","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1016\/S2352-3026(20)30366-5","article-title":"MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial","volume":"8","author":"Ferreri","year":"2021","journal-title":"Lancet Haematol"},{"issue":"10","key":"2025122310012400900_bib7","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1212\/WNL.0b013e31820f2d94","article-title":"Rituximab monotherapy for patients with recurrent primary CNS lymphoma","volume":"76","author":"Batchelor","year":"2011","journal-title":"Neurology"},{"issue":"4","key":"2025122310012400900_bib8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/blood.2024024168","article-title":"Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma","volume":"144","author":"Godfrey","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025122310012400900_bib9","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/bjh.18660","article-title":"Tafasitamab at the blood-brain barrier","volume":"201","author":"Rauschecker","year":"2023","journal-title":"Br J Haematol"},{"issue":"5","key":"2025122310012400900_bib10","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00280-020-04054-8","article-title":"Pharmacokinetics of polatuzumab vedotin in combination with R\/G-CHP in patients with B-cell non-Hodgkin lymphoma","volume":"85","author":"Shemesh","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"2025122310012400900_bib11","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2025122310012400900_bib12","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"issue":"14","key":"2025122310012400900_bib13","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1182\/blood-2013-06-453084","article-title":"How I treat CNS lymphomas","volume":"122","author":"Rubenstein","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2025122310012400900_bib14","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1158\/2159-8290.CD-23-0802","article-title":"Molecular determinants of sensitivity to polatuzumab vedotin in diffuse large B-cell lymphoma","volume":"14","author":"Corcoran","year":"2024","journal-title":"Cancer Discov"},{"issue":"7","key":"2025122310012400900_bib15","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1158\/1078-0432.CCR-23-3062","article-title":"Mechanistic modeling of intrathecal chemotherapy pharmacokinetics in the human central nervous system","volume":"30","author":"Li","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2025122310012400900_bib16","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.3324\/haematol.2021.278559","article-title":"Preventing central nervous system spread in diffuse large B-cell lymphoma - novel approaches needed","volume":"106","author":"Roschewski","year":"2021","journal-title":"Haematologica"},{"issue":"10","key":"2025122310012400900_bib17","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1093\/neuonc\/noae103","article-title":"Leptomeningeal metastases from solid tumors: a Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions","volume":"26","author":"Wilcox","year":"2024","journal-title":"Neuro Oncol"},{"issue":"2","key":"2025122310012400900_bib18","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2002-06-1636","article-title":"Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment","volume":"101","author":"Rubenstein","year":"2003","journal-title":"Blood"},{"issue":"18","key":"2025122310012400900_bib19","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1158\/1078-0432.CCR-24-0605","article-title":"A phase II study assessing long-term response to ibrutinib monotherapy in recurrent or refractory CNS lymphoma","volume":"30","author":"Grommes","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"23","key":"2025122310012400900_bib20","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1182\/bloodadvances.2019000989","article-title":"Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray","volume":"3","author":"Villa","year":"2019","journal-title":"Blood Adv"},{"issue":"8","key":"2025122310012400900_bib21","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJMc2306105","article-title":"Cell-of-origin subtypes and therapeutic benefit from polatuzumab vedotin","volume":"389","author":"Palmer","year":"2023","journal-title":"N Engl J Med"},{"issue":"35","key":"2025122310012400900_bib22","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1200\/JCO.23.00365","article-title":"High-dose methotrexate as CNS prophylaxis in high-risk aggressive B-cell lymphoma","volume":"41","author":"Lewis","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16","key":"2025122310012400900_bib23","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2021014506","article-title":"Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients","volume":"139","author":"Wilson","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2025122310012400900_bib24","doi-asserted-by":"crossref","first-page":"102924","DOI":"10.1016\/j.esmoop.2024.102924","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial","volume":"9","author":"Hurvitz","year":"2024","journal-title":"ESMO Open"},{"issue":"11","key":"2025122310012400900_bib25","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.annonc.2024.07.245","article-title":"Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022","volume":"35","author":"Freedman","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"2025122310012400900_bib26","doi-asserted-by":"crossref","first-page":"100502","DOI":"10.1016\/j.medj.2024.08.001","article-title":"The DEBBRAH trial: trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis","volume":"6","author":"Vaz Batista","year":"2025","journal-title":"Med"},{"issue":"12","key":"2025122310012400900_bib27","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat Med"},{"issue":"29","key":"2025122310012400900_bib28","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1200\/JCO.24.00553","article-title":"Sustained clinical benefit and intracranial activity of tarlatamab in previously treated small cell lung cancer: DeLLphi-300 trial update","volume":"42","author":"Dowlati","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025122310012400900_bib29","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"2025122310012400900_bib30","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"2025122310012400900_bib31","doi-asserted-by":"crossref","first-page":"102233","DOI":"10.1016\/j.esmoop.2024.102233","article-title":"Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and meta-analysis","volume":"9","author":"Michelon","year":"2024","journal-title":"ESMO Open"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6425\/2474999\/blooda_adv-2025-017181-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6425\/2474999\/blooda_adv-2025-017181-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T15:19:00Z","timestamp":1766503140000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/24\/6425\/547642\/Polatuzumab-vedotin-in-CNS-lymphoma-proof-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":31,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017181","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,23]]},"published":{"date-parts":[[2025,12,12]]}}}